Skip to main content
SpringerLink
Log in

Phase II study of chlorozotocin in islet cell carcinoma

A Southwest Oncology Group study

  • Original Articles
  • Chlorozotocin Islet Cell Carcinoma
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Summary

Seventeen patients with islet cell carcinoma received chlorozotocin (CTZ). Nine received 200 mg/m2 IV every 6 weeks and 8 received 100 mg/m2. Responses were seen in eight (2 complete, 5 partial, 1 minor) of 13 patients who had received no prior chemotherapy, and in zero of four who had recieved prior chemotherapy. Toxicity was mild in most patients and consisted predominantly in myelosuppressions; however, in one patient severe renal failure developed. CTZ may have activity comparable to streptozotocin in this group of patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Bisel HF, Ansfield FJ, Mason JH, Wilson WL (1970) Clinical studies with tubercidin administered by direct injection. Cancer Res 30:76

    Google Scholar 

  2. Broder LE, Carter SK (1973) Pancreatic islet cell carcinoma. II. Results of therapy with streptozotocin in 52 patients. Ann Intern Med 79:108

    Google Scholar 

  3. Erickson LC (1978) Measurement of DNA damage in hamster cells trcated with equitoxic and equi-metogenic doses of nitrosoureas. Proc Am Assoc Cancer Res 19:210

    Google Scholar 

  4. Gralla RJ, Tan CTC, Young CW (1979) Phase I trial of chlorozotocin. Cancer Treat Rep 63:17

    Google Scholar 

  5. Hoth D, Wooley P, Green D, McDonald J, Schein PS (1978) Phase I studies of chlorozotocin. Clin Pharmacol Ther 23:712

    Google Scholar 

  6. Johnston TP, McCaleb GS, Montgomery JA (1975) Synthesis of chlorozotocin, the 2-chloroethyl analog of the anticancer antibiotic streptozotocin. J Med Chem 18:104

    Google Scholar 

  7. Moertel CG (1973) Endocrine pancrease: In: Holland JF, Frei E (eds) Cancer Medicine. Lea & Febiger, Philadelphia, pp 1573–1596

    Google Scholar 

  8. Moertel CG (1975) Clinical management of advanced gastrointestinal cancer. Cancer 36:675

    Google Scholar 

  9. Moertel CG, Hanley JA, Johnson LA (1980) Streptozotocin alone compared with streptozotocin plus fluorouracil in the treatment of advanced islet cell carcinoma. N Engl J Med 303:1189

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Depatment of Hematology and Medical Oncology, The Cleveland Clinic Foundation, 9500 Euclid Avenue, 44106, Cleveland, Ohio, USA

    Ronald M. Bukowski

  2. Brooke Army Medical Center, San Antonio, USA

    Joseph D. McCracken

  3. Ohio State University Hospitals, Columnbus, USA

    Stanley P. Balcerzak

  4. University of Kansas Medical Center, Kansas, USA

    Carol J. Fabian

Authors
  1. Ronald M. Bukowski
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Joseph D. McCracken
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Stanley P. Balcerzak
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Carol J. Fabian
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bukowski, R.M., McCracken, J.D., Balcerzak, S.P. et al. Phase II study of chlorozotocin in islet cell carcinoma. Cancer Chemother. Pharmacol. 11, 48–50 (1983). https://doi.org/10.1007/BF00257417

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00257417

Keywords

Search

Navigation